List of Excipients in Branded Drug PACLITAXEL PROTEIN BOUND PARTICLES ALBUMIN BOUND

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
American Regent Inc	PACLITAXEL PROTEIN BOUND PARTICLES ALBUMIN BOUND	paclitaxel	0517-4300	ALBUMIN HUMAN
American Regent Inc	PACLITAXEL PROTEIN BOUND PARTICLES ALBUMIN BOUND	paclitaxel	0517-4300	HYDROCHLORIC ACID
American Regent Inc	PACLITAXEL PROTEIN BOUND PARTICLES ALBUMIN BOUND	paclitaxel	0517-4300	SODIUM HYDROXIDE

Paclitaxel Protein-Bound Particles: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 20, 2026

Paclitaxel protein-bound particles, marketed as Abraxane, use human albumin as the principal excipient and delivery carrier. The formulation eliminates polyoxyethylated castor oil and ethanol used in conventional paclitaxel injection, reducing solvent-related hypersensitivity risk and removing the need for routine corticosteroid and antihistamine premedication. Its commercial value rests on three elements: a differentiated solvent-free formulation, established oncology indications, and a technically more difficult generic-development pathway than conventional paclitaxel.

The principal commercial risks are price erosion from complex injectable competitors, dependence on human albumin supply, mature-market oncology competition, and patent or regulatory challenges to the formulation and manufacturing process.

What is the formulation strategy for paclitaxel protein-bound particles?

Abraxane is a lyophilized injectable formulation containing paclitaxel and human albumin. The product is reconstituted with normal saline to produce a colloidal suspension of albumin-bound paclitaxel particles, generally described as approximately 130 nanometers in diameter.

Formulation element	Role
Paclitaxel	Antineoplastic active ingredient
Human albumin	Protein carrier, stabilizer, and particle-forming excipient
Sodium chloride injection	Reconstitution vehicle
Water for injection	Used during manufacturing and removed during lyophilization
Cremophor EL	Absent
Ethanol	Absent

The core excipient strategy is functional rather than inert. Albumin is part of the delivery architecture. It enables particle formation, provides colloidal stabilization, supports parenteral administration, and differentiates the product from solvent-based paclitaxel.

The commercial product is supplied as a 100 mg single-dose vial. The reconstituted concentration is 5 mg/mL. The formulation does not contain preservatives and is administered intravenously over approximately 30 minutes under the U.S. prescribing information. [1]

Why is human albumin commercially important in this formulation?

Human albumin is the critical supply-chain and intellectual-property input. Its use affects cost, manufacturing capacity, regulatory controls, and product comparability.

Albumin creates several barriers for competing manufacturers:

1. The supplier must provide pharmaceutical-grade human albumin with controlled viral safety, purity, aggregation, and lot-to-lot consistency.
2. The manufacturer must reproduce the particle-size distribution and paclitaxel loading profile.
3. The product must maintain stability through freeze-drying, reconstitution, storage, and infusion.
4. The applicant must demonstrate that the final drug product is comparable despite the absence of a conventional solubilizing surfactant.
5. The manufacturing process must control shear, homogenization, filtration, drying, and reconstitution behavior.

Albumin also creates a cost opportunity. A manufacturer that secures long-term albumin supply, develops an efficient particle-production process, or uses a lower-cost regional source can improve gross margin without changing the active ingredient.

The key technical risk is that albumin is not merely a bulking agent. Changes in albumin grade, fatty-acid content, aggregation, particle formation, or surface chemistry can affect pharmacokinetics, dose delivery, and clinical performance.

What excipient alternatives could compete with albumin-bound paclitaxel?

Albumin is difficult to replace without changing the product’s regulatory and commercial identity. Potential alternative strategies include polymeric nanoparticles, liposomes, phospholipid carriers, cyclodextrin systems, and surfactant-free crystalline suspensions.

Delivery strategy	Potential advantage	Main limitation
Albumin-bound particles	Established clinical profile; solvent-free; no routine premedication	Albumin sourcing and complex manufacturing
Liposomal paclitaxel	Encapsulation and controlled release	Different pharmacokinetics and likely new-drug regulatory pathway
Polymeric nanoparticles	Tunable release and targeting	Polymer safety, scale-up, and residual-solvent controls
Phospholipid formulations	Potentially lower excipient burden	Particle stability and infusion performance
Solvent-based paclitaxel	Low-cost, established generic supply	Hypersensitivity precautions and solvent toxicity
Oral or implantable delivery	Reduced infusion burden	Bioavailability and formulation complexity

An alternative formulation cannot generally rely on Abraxane’s abbreviated pathway merely because it contains paclitaxel. The regulatory burden depends on the dosage form, inactive ingredients, pharmacokinetic profile, route, and level of product sameness.

What FDA indications support the commercial opportunity?

The FDA approved Abraxane in 2005 for metastatic breast cancer after failure of combination chemotherapy or relapse within six months of adjuvant chemotherapy. The label later expanded to include locally advanced or metastatic non-small-cell lung cancer in combination with carboplatin and metastatic adenocarcinoma of the pancreas in combination with gemcitabine. [1]

Indication	Commercial relevance
Metastatic breast cancer	Established taxane market with high generic competition
Non-small-cell lung cancer	Large treatment population and combination use
Metastatic pancreatic adenocarcinoma	Higher-value indication with continued demand for combination therapy
Other off-label oncology use	Potential demand but limited direct label protection

The pancreatic cancer indication is especially relevant to commercial forecasting because it created a large, durable use case for a solvent-free albumin-bound formulation. The product competes against gemcitabine combinations, FOLFIRINOX, conventional taxanes, and newer oncology regimens.

What patents protect paclitaxel protein-bound particles?

The strongest historical patent protection covered albumin-bound particles containing paclitaxel and related manufacturing methods. Relevant U.S. patents associated with the Abraxane technology include:

Patent	General subject matter	Strategic relevance
U.S. Patent No. 6,749,868	Albumin-bound taxane particles and related compositions	Foundational formulation protection
U.S. Patent No. 7,820,788	Protein-bound particle compositions and preparation methods	Manufacturing and particle-technology protection
U.S. Patent No. 8,343,919	Related protein-bound particle technology	Potential formulation or process coverage
U.S. Patent No. 8,969,371	Later-generation particle or process claims	Supplemental protection depending on listed claims

The commercial effect of these patents depends on claim scope, terminal disclaimers, patent-term adjustment, patent-term extension, Orange Book listing, and any litigation or settlement history. Foundational patents have generally expired or approached expiration, while later patents can remain relevant to a generic applicant’s launch analysis.

A definitive patent clearance requires claim-level review of the current Orange Book, Patent Center records, prosecution history, and any applicable district-court or Federal Circuit decisions. [2][3]

When does Abraxane lose exclusivity?

Abraxane’s principal regulatory exclusivity periods have expired. The product received standard new-drug approval in 2005, and its pancreatic cancer indication was approved in 2013. Any remaining market protection depends primarily on patents, regulatory requirements, manufacturing complexity, and commercial execution rather than unexpired orphan or new-chemical-entity exclusivity. [1][4]

The important distinction is between regulatory exclusivity and practical market exclusivity:

Protection type	Status or commercial effect
New chemical entity exclusivity	Not applicable to the mature product
Orphan-drug exclusivity	Historical indication-specific protection; expiration depends on the designation and approval date
Pediatric exclusivity	No core market conclusion without current FDA records
Formulation and process patents	Potentially relevant through listed or unexpired claims
Trade secrets	May remain important for particle manufacturing and scale-up
Albumin supply agreements	Can create operational barriers without blocking legal entry

The expected generic-entry date cannot be determined from the original approval date alone. It depends on the status of listed patents, Paragraph IV certifications, litigation, FDA approval timing, and any settlement restrictions.

What is the Orange Book status of Abraxane?

Abraxane is an FDA-approved prescription drug listed in the Orange Book under paclitaxel protein-bound particles for injectable suspension. The Orange Book is the controlling source for current patent listings, use codes, dosage-form information, and approved therapeutic-equivalence ratings. [2]

For commercial diligence, the following Orange Book issues matter:

• Whether a formulation or process patent remains listed.
• Whether a listed patent has expired or been delisted.
• Whether an ANDA applicant has certified Paragraph IV against a listed patent.
• Whether a method-of-use patent covers pancreatic, breast, or lung cancer treatment.
• Whether a generic applicant can carve out a patented indication under a section viii statement.
• Whether FDA grants a therapeutic-equivalence rating to a competing product.

Method-of-use patents can delay or complicate entry even when the active ingredient and dosage form are no longer protected. A skinny-label strategy may permit entry for non-protected indications, but it can reduce the commercial value of the generic and create labeling and litigation risk.

Which companies are challenging the Abraxane market?

The principal competitive groups are conventional paclitaxel manufacturers, complex-injectable developers, oncology-focused generic companies, and developers of alternative nanoparticle formulations.

Relevant competitive categories include:

Conventional paclitaxel manufacturers

Generic paclitaxel is supplied by multiple manufacturers and is materially cheaper than Abraxane. Its disadvantages are solvent exposure, infusion reactions, premedication requirements, and different administration logistics.

Complex injectable manufacturers

Companies with sterile manufacturing, lyophilization, nanoparticle, or biologics-adjacent capabilities are better positioned to develop an albumin-bound competitor. The technical hurdle is higher than for a conventional small-molecule injectable.

Alternative nanoparticle developers

Alternative formulations may compete clinically without being therapeutically equivalent. They can pursue differentiated claims such as reduced infusion time, lower toxicity, improved tolerability, or use in populations unable to receive solvent-based paclitaxel.

Biosimilar developers

Abraxane is not a biologic drug for purposes of ordinary market analysis simply because it contains human albumin. A competing albumin-bound paclitaxel product would generally be evaluated as a complex drug product through an abbreviated or full application pathway, not automatically through the biosimilar pathway. The exact route depends on FDA classification and the applicant’s demonstration strategy.

What generic entry risks exist for Abraxane?

Generic-entry risk is moderate to high over the long term, but the timing and scale of erosion are less predictable than for conventional paclitaxel.

Risk factor	Effect on entry
Expired core composition patents	Increases entry probability
Complex particle attributes	Raises development cost
Human albumin supply	Adds manufacturing risk
Bioequivalence requirements	May require extensive comparative data
Method-of-use patents	Can restrict labeled indications
Hospital purchasing	Favors lower-cost substitutes
Oncology physician familiarity	Supports incumbent persistence
Payer pressure	Accelerates substitution
Manufacturing failures	Can delay approval or commercial launch

A successful generic may initially launch with a limited indication set or at-risk exposure after Paragraph IV litigation. Commercial erosion may be gradual if hospitals require evidence of consistent particle performance, supply reliability, and clinical interchangeability.

What patent litigation and Paragraph IV issues affect the product?

The principal litigation exposure arises from ANDA applicants challenging listed formulation, composition, method-of-use, or manufacturing patents. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. The NDA holder may file suit within 45 days, triggering an FDA approval stay of up to 30 months, subject to statutory exceptions. [5]

For Abraxane, litigation analysis should focus on:

• Patent validity under obviousness and written-description standards.
• Whether claims require a specific particle-size range.
• Whether claims require albumin-paclitaxel binding characteristics.
• Whether process claims are infringed by an independent manufacturing route.
• Whether a generic applicant can omit pancreatic or other protected uses.
• Whether settlement terms permit a licensed or date-certain launch.

Publicly available patent and court records should be reconciled with the current Orange Book. A historical patent challenge does not establish current market entry unless the challenged patent, settlement, and FDA status remain operative.

How strong is the Abraxane patent estate?

The estate is strongest where it covers a narrow technical combination that a competitor must reproduce to obtain comparable performance: albumin-bound paclitaxel particles, defined particle attributes, reconstitution behavior, and manufacturing parameters.

Its effective strength is weaker where:

• The claims broadly cover known paclitaxel or albumin concepts.
• Foundational patents have expired.
• A competitor can use a different carrier or process.
• The FDA permits approval based on a different demonstration package.
• A generic applicant can carve out protected uses.
• Trade-secret manufacturing knowledge cannot be enforced against independent development.

The most durable protection may come from process know-how, analytical methods, supplier qualification, and clinical adoption rather than from a single composition patent.

What commercial opportunities exist for excipient suppliers and drug developers?

Albumin supply and qualification

Pharmaceutical-grade albumin suppliers can capture value through long-term contracts, dual-source qualification, regional manufacturing, and improved impurity controls. Supply reliability is commercially important because a substitute albumin source can trigger comparability work.

Licensed formulation platforms

Drug developers can license albumin-bound particle technology for other cytotoxic agents, immunomodulators, or poorly soluble compounds. The opportunity is strongest when the formulation solves a clear clinical problem, such as solvent toxicity or infusion time.

Regional generic development

Manufacturers in markets with lower development costs may pursue albumin-bound paclitaxel for countries where Abraxane pricing remains high and patent barriers have expired. Regulatory requirements vary substantially by jurisdiction.

Hospital and payer positioning

A lower-priced competitor can target hospitals seeking to reduce drug-acquisition cost. The incumbent can defend share through supply continuity, physician familiarity, pancreatic cancer experience, and reduced premedication requirements.

Manufacturing partnerships

Contract development and manufacturing organizations with sterile lyophilization, high-pressure homogenization, nanoparticle characterization, and albumin handling capabilities can become strategic partners for entrants.

How does Abraxane compare with conventional paclitaxel?

Attribute	Abraxane	Conventional paclitaxel
Carrier or solvent	Human albumin-bound particles	Cremophor EL and ethanol
Premedication	Generally not required by label	Required because of hypersensitivity risk
Infusion time	Approximately 30 minutes	Often longer, depending on regimen
Manufacturing complexity	High	Established and relatively lower
Cost position	Premium	Generic low-cost
Generic substitution	Technically difficult	Broadly available
Key differentiation	Solvent-free delivery and albumin particle system	Low acquisition cost

Abraxane’s value proposition is strongest when solvent avoidance, premedication reduction, infusion convenience, or regimen-specific clinical evidence offsets its premium price.

What is the revenue exposure from generic competition?

The revenue impact depends on whether a competitor is therapeutically equivalent, whether it launches across all indications, and how quickly hospitals adopt it. A single approved generic with reliable supply could pressure price and volume. Several entrants would likely produce sharper erosion.

Bristol Myers Squibb reports Abraxane as part of its product portfolio following the Celgene acquisition. Historical annual sales have been approximately $1 billion or more in certain years, making the product commercially material even after loss of regulatory exclusivity. [6]

The most exposed revenue segments are high-volume breast and lung cancer use. Pancreatic cancer demand may be more resilient because of entrenched treatment pathways and the product’s established use with gemcitabine.

Key Takeaways

• Human albumin is the central excipient and the principal formulation differentiator.
• Abraxane avoids Cremophor EL and ethanol, supporting reduced solvent-related administration burdens.
• The product has FDA-approved indications in metastatic breast cancer, non-small-cell lung cancer, and metastatic pancreatic adenocarcinoma.
• Regulatory exclusivity has expired or is no longer the primary barrier to entry.
• Remaining protection depends on current Orange Book patents, method-of-use claims, manufacturing know-how, and supply-chain execution.
• A competing albumin-bound product faces higher technical and regulatory barriers than conventional paclitaxel.
• The strongest commercial opportunities are albumin supply, complex-injectable manufacturing, regional generic entry, and licensing of albumin-bound delivery technology.
• Generic erosion is likely to be slower and more technically constrained than for ordinary paclitaxel, but hospital price pressure remains substantial.

FAQs

Is albumin in Abraxane an active ingredient or an excipient?

Human albumin is an excipient and delivery carrier. Paclitaxel is the active pharmaceutical ingredient.

Does Abraxane contain Cremophor EL?

No. Abraxane does not use Cremophor EL or ethanol as the paclitaxel solubilizing system.

Can a generic paclitaxel product substitute automatically for Abraxane?

No. Conventional paclitaxel and albumin-bound paclitaxel have different formulations, administration requirements, and regulatory characteristics. Automatic substitution depends on FDA therapeutic-equivalence status and applicable state pharmacy law.

Is albumin-bound paclitaxel a biosimilar?

Not automatically. The presence of human albumin does not by itself make the product a biosimilar. A competitor would need to follow the FDA pathway applicable to the proposed product and formulation.

What is the largest barrier to launching a generic Abraxane?

The largest barrier is reproducing the albumin-paclitaxel particle system at commercial scale while demonstrating acceptable quality, bioequivalence or comparability, stability, and reliable sterile manufacturing.

References

1. U.S. Food and Drug Administration. (2024). Abraxane (paclitaxel protein-bound particles for injectable suspension) prescribing information.
2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. United States Patent and Trademark Office. (2025). Patent Center patent records for U.S. Patent Nos. 6,749,868; 7,820,788; 8,343,919; and 8,969,371.
4. U.S. Food and Drug Administration. (2013). FDA approves Abraxane plus gemcitabine for metastatic pancreatic cancer.
5. U.S. Food and Drug Administration. (2024). Guidance for industry: 180-day exclusivity and 30-month stays under the Hatch-Waxman Amendments.
6. Bristol Myers Squibb. (2024). Annual report and product sales disclosures.